1 min left

0% read

Genesis Therapeutics

Infrastructure

Software

Technology Company

Burlingame, California, USA

Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery

Genesis Therapeutics

Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery.

We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines.

Genesis raised its $52M Series A from top tech and biotech investors, Andreessen Horowitz, Rock Springs, and T. Rowe Price.

Story: techcrunch.com

We deploy our technology to accelerate a pipeline of several internal drug programs.

Furthermore, Genesis has announced two significant, multi-target collaborations with Genentech and with Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size.

Now we are scaling the team and technology to support many more programs in parallel as well as increasingly difficult protein targets.

We currently have a team (genesistherapeutics.ai/company.html#team) of about 35 people, split 50/50 between our ML/software team and our biochem team of veteran drug hunters in our own wetlab space. Our ML and software engineers are top-notch—many graduates from MIT, UC Berkeley, and Stanford. They previously worked at OpenAI, Google, Facebook, MemSQL, Jane Street, Dropbox, etc.

We're recruiting pure ML research scientists and software engineers (no bio or chem experience expected) to further our core AI platform as well as scale our drug pipeline.

Likewise, we have several openings in chemistry and biology to join our team of biotech and pharma veterans who are deploying the Genesis ML platform to discover novel drug candidates.

Please apply on our website, or feel free to reach out via email directly: [email]

Frequently Asked Questions About Genesis Therapeutics

Genesis Therapeutics is an infrastructure company. Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery

Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery. We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines. Genesis raised its $52M Series A from top tech + biotech investors, Andreessen Horowitz, Roc.

When evaluating any crypto company, check their official website, social media presence, regulatory status, and user reviews. Genesis Therapeutics is listed in our verified company directory — review their full profile for team details, founding date, and company background.

Genesis Therapeutics operates in the infrastructure sector of the cryptocurrency industry. Compare Genesis Therapeutics with other infrastructure companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using Genesis Therapeutics, research their track record, verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. Genesis Therapeutics is based in Burlingame, California, USA. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

Genesis Therapeutics is based in Burlingame, California, USA, North America, with offices in Burlingame, California, USA, San Diego, California, USA.

Genesis Therapeutics has 58 employees.

Genesis Therapeutics Details

Genesis Therapeutics Offices (6)

Genesis Therapeutics Tags

More About Genesis Therapeutics

Work Model Details

Employees engage in a combination of remote and on-site work.

Latest from Academy

Blockchain

Why Circle and Paxos Both Chose Aleo for Stablecoins

By 2025, stablecoins will have been traded $33 trillion. Less than 1% of businesses issue employee salaries in cryptocurrency. The biggest blocker is that sending salary payments, vendor invoices, and treasury balances on public blockchains exposes that information to anyone who pulls it up on a block explorer. Privacy-focused Layer 1 Aleo was made for enterprises trying to solve this problem.

Mia Halland14h ago

10m read

Trading Analysis

Bounce Token Price Just Hit a Critical Inflection Point

AUCTION is trading at $4.74, only 50% above its historic low of $3.16 and 93.3% below its all-time high of $70.44. The proximity to the bottom isn't coincidental,it's a structural signal. While 24-hour trading volume increased 33.9% to $6.07 million, the token was flashing patterns worthy of a forensic breakdown.

Archie Dutton17h ago

8m read

Altcoins

ChainOpera AI Has 100,000 Developers and a 99% Price Drop

ChainOpera AI has raised over $17M. They have a dev community of 100,000. Over 3 million total users on BNB Chain. COAI is trading at $0.26, down approximately 99% from its all-time high price near $43.81. This insane amount of price disparity vs platform-level adoption is what makes this worth examining. There are nontrivial risks. Whale mint risk. Copy-paste killer app claims. The NOFX code plagiarism scandal.

Crypto News Navigator18h ago

8m read